ArticleScientific reports2026
Interferon-gamma release assay screening before solid organ transplantation in a low-incidence country: a prospective single-center cohort study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The risk of tuberculosis is increased after solid organ transplantation (SOT) and associated with morbidity and mortality. Pre-transplantation screening and treatment for tuberculosis infection (TBI) is recommended. Aims of this prospective cohort study were determining the prevalence of positive pre-transplantation interferon-gamma release assays (IGRAs), risk factors for a positive result, and describe TBI management. We included SOT candidates from 2020 to 2023 at Rigshospitalet, Denmark with a pre-transplantation IGRA. Data were collected from records and the Danish Microbiology Database. Of 586 patients, 564 (96%) had a pre-transplantation IGRA. Twenty-two (4%) had positive, 537 (95%) negative, and 5 (1%) indeterminate results. Risk factors for a positive IGRA were diabetes (14/480 (3%) without diabetes, 8/84 (10%) with diabetes, aOR 3.07, 95% CI 1.14-7.78), birth in other low-incidence countries (4/24 (17%) vs. 8/463 (2%), aOR 10.14, CI 2.48-35.95) or medium-/high-incidence countries (10/77 (13%), aOR 8.22, CI 3.11-22.43), and alcohol use (aOR 2.75, CI 1.04-7.15). Seventeen patients had TBI; 16 (94%) treated with isoniazid for 6 months, one (6%) with rifampicin for 4 months; treatment discontinued in one case. In conclusion, IGRA screening coverage was high. Positive IGRAs were associated with birth in other low- or medium-/high-incidence countries, diabetes, alcohol use. TBI treatment was well tolerated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.